• Preparation: 3 IFS sessions (90 min each, weekly) before the first MDMA dose

• Dosing: 3 MDMA + IFS sessions (6–8 hrs each), spaced 3–4 weeks apart

• Integration: 9 IFS sessions (90 min; 3 after each dose within the first two weeks)

Planned sites in England and the United States, with Australia under consideration. Final sites will be announced after regulatory and funding approvals.

• Lead Therapist (IFS-trained): primary clinician for all prep, all 3 dosing days, and all 9 integration sessions; owns case formulation, documentation, and fidelity.

• Co-Lead (IFS-trained preferred; ED-specialized acceptable with IFS foundations): joins the final prep session, all 3 dosing days, and selected integrations; tracks safety, anchors the frame, and co-documents.

• Coverage: two therapists present at all times during MDMA dosing; brief handovers documented.

• Leads: 4–8 participants/year

  • ~39 face-to-face hours/participant (prep + dosing + integration)

  • With notes, coordination, and supervision: ~55–65 hours/participant

• Co-Leads: dosing days + select prep/integration; plan for ~30–45 hours/participant

• Holds for full-day dosing and post-dose debriefs are required.

• Many prep and integration sessions may be in person or hybrid, depending on site policy and regulations

• All MDMA dosing sessions are in-person at the study site

Minimum

• Licensed mental health clinician (country-appropriate), in good standing, with professional indemnity/malpractice coverage

• IFS Level 1 training (Level 2/3 preferred).

• Eating disorder experience (≥ 1 year in outpatient, inpatient, or residential ED settings OR ≥ 10 cases of anorexia nervosa OR willingness to completed stud-specific ED training).

• MDMA-assisted therapy (MDMA-AT) training (verified by certificate or confirmation letter sent from training organization) or or willingness to complete stud-specific MDMA-AT training).

• Good Clinical Practice (GCP) training (verified by up-to-date certificate from training organization) or willingness to complete GCP training before participant contact, and willingness to complete session notes within 24 h and report AEs/SAEs per GCP.

• Willingness to complete study-specific protocol training.

• Good Clinical Practice (GCP) certificate (or completion prior to participant contact)

• Willingness to be video-recorded for fidelity and safety

Strongly preferred

• Prior psychedelic-assisted therapy experience (clinical or research)

• Competence with trauma, dissociation, suicidality risk management

• Comfort working in a dyad with continuous medical and video monitoring

• Market-rate, trial-funded compensation aligned with role and country norms

• Day-rates for dosing days; hourly or per-session rates for prep/integration; paid supervision/admin time

• Training stipends for study-required modules (where allowable)

• Exact rates are finalized per site once funding is confirmed

• Therapist registry opens now (to begin outreach, vetting, and training queues)

• Target site activation:2027–2028 (funding & regulatory dependent)

• Early applicants may be invited to pre-study trainings and mock sessions